Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: a randomized clinical trial.

IMPORTANCE Increasing evidence suggests a relationship between poor sleep and the risk of developing Alzheimer disease. A previous study found an effect of sleep on β-amyloid (Aβ), which is a key protein in Alzheimer disease pathology. OBJECTIVE To determine the effect of 1 night of total sleep deprivation on cerebrospinal fluid Aβ42 protein levels in healthy middle-aged men. DESIGN, SETTING, AND PARTICIPANTS The Alzheimer, Wakefulness, and Amyloid Kinetics (AWAKE) study at the Radboud Alzheimer Center, a randomized clinical trial that took place between June 1, 2012, and October 1, 2012. Participants were cognitively normal middle-aged men (40-60 years of age) with normal sleep (n = 26) recruited from the local population. INTERVENTIONS Participants were randomized to 1 night with unrestricted sleep (n = 13) or 1 night of total sleep deprivation (24 hours of wakefulness) (n = 13). MAIN OUTCOMES AND MEASURES Sleep was monitored using continuous polysomnographic recording from 3 pm until 10 am. Cerebrospinal fluid samples were collected using an intrathecal catheter at defined times to compare cerebral Aβ42 concentrations between evening and morning. RESULTS A night of unrestricted sleep led to a 6% decrease in Aβ42 levels of 25.3 pg/mL (95% CI [0.94, 49.6], P = .04), whereas sleep deprivation counteracted this decrease. When accounting for the individual trajectories of Aβ42 over time, a difference of 75.8 pg/mL of Aβ42 was shown between the unrestricted sleep and sleep deprivation group (95% CI [3.4, 148.4], P = .04). The individual trajectories of evening and morning Aβ42 concentrations differed between the unrestricted sleep and sleep deprivation groups (P = .04) in contrast to stable Aβ40, tau, and total protein levels. CONCLUSIONS AND RELEVANCE Sleep deprivation, or prolonged wakefulness, interferes with a physiological morning decrease in Aβ42. We hypothesize that chronic sleep deprivation increases cerebral Aβ42 levels, which elevates the risk of Alzheimer disease. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01194713.

[1]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[2]  William J. Jagust,et al.  Lifespan brain activity, β-amyloid, and Alzheimer's disease , 2011, Trends in Cognitive Sciences.

[3]  G. Borm,et al.  Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers , 2012, Neurobiology of Aging.

[4]  David M Holtzman,et al.  Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.

[5]  D. Dinges,et al.  The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. , 2003, Sleep.

[6]  D. Holtzman,et al.  Neuronal activity regulates extracellular tau in vivo , 2014, The Journal of experimental medicine.

[7]  C. Masters,et al.  Distinct sites of intracellular production for Alzheimer's disease Aβ40/42 amyloid peptides , 1997, Nature Medicine.

[8]  Martin Hallbeck,et al.  Spreading of amyloid-β peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance , 2014, Neurobiology of Disease.

[9]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[10]  Giorgio F. Gilestro,et al.  Widespread Changes in Synaptic Markers as a Function of Sleep and Wakefulness in Drosophila , 2009, Science.

[11]  Chengjie Xiong,et al.  Sleep quality and preclinical Alzheimer disease. , 2013, JAMA neurology.

[12]  G. Tononi,et al.  Cortical Firing and Sleep Homeostasis , 2009, Neuron.

[13]  D. Bennett,et al.  Sleep Fragmentation and the Risk of Incident Alzheimer's Disease and Cognitive Decline in Older Persons. , 2013, Sleep.

[14]  D. Bennett,et al.  Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. , 2013, JAMA neurology.

[15]  David M Holtzman,et al.  Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. , 2005, Neuron.

[16]  Daniel J. R. Christensen,et al.  Sleep Drives Metabolite Clearance from the Adult Brain , 2013, Science.

[17]  M. D. de Leon,et al.  GREATER RISK OF ALZHEIMER'S DISEASE IN OLDER ADULTS WITH INSOMNIA , 2011, Journal of the American Geriatrics Society.

[18]  S. Overeem,et al.  Reciprocal interactions between sleep, circadian rhythms and Alzheimer's disease: Focus on the role of hypocretin and melatonin , 2013, Ageing Research Reviews.

[19]  Yo-El Ju,et al.  Effects of Age and Amyloid Deposition on A␤ Dynamics in the Human Central Nervous System , 2022 .

[20]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[21]  David L. Brody,et al.  Amyloid-β Dynamics Correlate with Neurological Status in the Injured Human Brain , 2008, Science.

[22]  Steven Mennerick,et al.  Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.

[23]  D. Holtzman,et al.  Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. , 2001, Journal of Alzheimer's disease : JAD.

[24]  D. Holtzman,et al.  Amyloid-beta dynamics in the injured human brain , 2009, Alzheimer's & Dementia.

[25]  Susan M Resnick,et al.  Self-reported sleep and β-amyloid deposition in community-dwelling older adults. , 2013, JAMA neurology.

[26]  D. Llano,et al.  Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels , 2012, Alzheimer's & Dementia.

[27]  A. Chesson,et al.  The American Academy of Sleep Medicine (AASM) Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications , 2007 .

[28]  Christina A. Wilson,et al.  Presenilins are not required for Aβ42 production in the early secretory pathway , 2002, Nature Neuroscience.

[29]  Seiji Nishino,et al.  Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle , 2009, Science.

[30]  D. Perani,et al.  FLUCTUATIONS OF CSF AMYLOID-β LEVELS: IMPLICATIONS FOR A DIAGNOSTIC AND THERAPEUTIC BIOMARKER , 2007, Neurology.